drugset / Trial / NCT05272865

Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

NCT05272865

Phase 1/2 Unknown 334 enrolled LaSanta S A S
RandomizedParallel-groupOpen-labelOther

Summary

Study based on the pharmacokinetic, pharmacodynamic, safety and stability evaluation of 3 standardized formulations of THC, to be used in healthy volunteers and post-chemotherapy patients as an adjuvant in the symptomatic treatment of the latter in discomfort associated with cancer treatment, with the aim of possible new therapeutic entities.

Timeline

Start
2023-08-15
Primary completion
2024-02-15
Completion
2024-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject CBC Unknown 5 mg/ml Oral
Subject CBG Unknown 5 mg/ml Oral
Subject Dronabinol Other / unclassified 5 mg/ml Oral
Subject Δ9-THC Unknown 5 mg/ml Oral